Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized antibiotic dosing could save lives in the ICU

NCT ID NCT07085624

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find the best way to dose the antibiotic ceftazidime for patients in intensive care with serious infections. Many ICU patients don't get enough of the drug because their bodies process it differently. The researchers will test a personalized dosing plan to keep antibiotic levels effective but safe. About 128 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusionn criteria: * Patient hospitalized in intensive care unit for an expected duration of at least 72 hours, with an infection for which initiation of ceftazidime therapy is being considered. * Patient with an arterial catheter for blood sampling. * Patients affiliated to or entitled under a social security scheme. Exclusion Criteria: * Pregnant woman, parturient, nursing mother; * Person deprived of liberty, hospitalized without consent, * Adults under legal protection (guardianship-curatorship) * Patients undergoing extra-renal purification or whose CKD-EPI at the start of treatment is less than 15 ml/min.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infection in icu are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Pseudomonas aeruginosa infectious disease Pseudomonas infection Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infection in icu Pseudomonas aeruginosa infection Sepsis Septic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU GRENOBLE, Médecine intensive

    Grenoble, 38043, France

  • CHU Nord, Médecine intensive et réanimation

    Marseille, 13915, France

  • CHU ST-ETIENNE - Médeine Intensive Réanimation

    Saint-Etienne, 42055, France

  • CHU ST-ETIENNE, Médecine intensive Réanimation B

    Saint-Etienne, 42055, France

  • CHU ST-ETIENNE, Réanimation Néphrologie

    Saint-Etienne, 42055, France

  • HCL Croix Rousse, Médecine intensive réanimation

    Lyon, 69004, France

  • HCL Hôpital Edouard Herriot, Médecine intensive et réanimation

    Lyon, 69437, France

  • HCL Hôpital Lyon Sud, Médecine intensive réanimation

    Pierre-Bénite, 69495, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.